Skip to main content

TSC1 Gene Mutation clinical trials at UC Davis
1 research study open to eligible people

  • Experimental targeted therapy, Sapanisertib, for locally advanced or metastatic bladder cancer with TSC1 and/or TSC2 mutations

    β€œCan experimental targeted therapy, Sapanisertib, stop the growth of tumor cells by blocking some of the enzymes needed for cell growth?”

    open to eligible people ages 18 years and up

    This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and/or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Sacramento, California and other locations

Last updated: